Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - galantamine hydrobromide, quantity: 20.512 mg - capsule, modified release - excipient ingredients: magnesium stearate; povidone; hydrogenated vegetable oil; colloidal anhydrous silica; sodium lauryl sulfate; polyvinyl acetate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; allura red ac; potable water; gelatin

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - galantamine hydrobromide, quantity: 10.256 mg - capsule, modified release - excipient ingredients: magnesium stearate; povidone; hydrogenated vegetable oil; titanium dioxide; allura red ac; potable water; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; colloidal anhydrous silica; polyvinyl acetate

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 8 mg - galantamine tablets are indicated for the treatment of mild to moderate dementia of the alzheimer’s type. galantamine tablets are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. in studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically. galantamine hydrobromide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in rats, administration of galantamine (oral doses of 2, 8, or 16 mg/kg/day), from day 14 (females) or day 60 (males) prior to mating and continuing in females through the period of organogenesis, resulted in an increased incidence of fetal skeletal

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide -

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 8 mg

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

avera mckennan hospital - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 12 mg

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

rebel distributors corp - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine hydrobromide 8 mg - razadyne® er/razadyne® (galantamine hydrobromide) is indicated for the treatment of mild to moderate dementia of the alzheimer's type. razadyne® er/razadyne® (galantamine hydrobromide) is contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

avera mckennan hospital - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 4 mg